BioSyent Inc. RX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 40.31M | 33.31M | 30.82M | 30.16M | 28.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 40.31M | 33.31M | 30.82M | 30.16M | 28.30M |
| Cost of Revenue | 10.73M | 8.11M | 7.22M | 6.80M | 6.17M |
| Gross Profit | 29.57M | 25.20M | 23.60M | 23.37M | 22.13M |
| SG&A Expenses | 18.90M | 16.20M | 15.20M | 14.83M | 14.08M |
| Depreciation & Amortization | 1.11M | 510.10K | 300.80K | 300.80K | 300.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.75M | 24.85M | 22.82M | 22.03M | 20.65M |
| Operating Income | 9.56M | 8.45M | 8.00M | 8.14M | 7.65M |
| Income Before Tax | 9.69M | 8.81M | 8.61M | 8.44M | 7.97M |
| Income Tax Expenses | 2.55M | 2.26M | 2.16M | 2.27M | 2.05M |
| Earnings from Continuing Operations | 7.14 | 6.54 | 6.45 | 6.18 | 5.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.14M | 6.54M | 6.45M | 6.18M | 5.92M |
| EBIT | 9.56M | 8.45M | 8.00M | 8.14M | 7.65M |
| EBITDA | 10.86M | 9.22M | 8.59M | 8.65M | 8.08M |
| EPS Basic | 0.63 | 0.58 | 0.57 | 0.55 | 0.52 |
| Normalized Basic EPS | 0.55 | 0.50 | 0.48 | 0.48 | 0.45 |
| EPS Diluted | 0.62 | 0.57 | 0.56 | 0.54 | 0.51 |
| Normalized Diluted EPS | 0.54 | 0.49 | 0.47 | 0.47 | 0.44 |
| Average Basic Shares Outstanding | 45.25M | 45.11M | 45.05M | 45.28M | 45.61M |
| Average Diluted Shares Outstanding | 46.24M | 46.11M | 46.03M | 46.23M | 46.55M |
| Dividend Per Share | 0.15 | 0.15 | 0.14 | 0.14 | 0.14 |
| Payout Ratio | 24.01% | 25.53% | 24.99% | 25.50% | 26.15% |